Peter Blaney

Peter Blaney is a career biotechnology entrepreneur and investor who has spent roughly 30 years starting, financing, and running early-stage life-science companies. By his firm's own description, his work has "led to products in biofuels, agricultural biotech, antiviral therapeutics, drug delivery and molecular diagnostics." He describes his experience as spanning the full spectrum of biotechnology — both founding companies and leading investments across biofuels, bioprocessing, agricultural biotech, and biopharmaceuticals.

Blaney is the founder and CEO of Induran Ventures Inc., a self-styled "Venture Philanthropy General Partner" based in Kingston, Ontario, whose tagline is "Where Venture Meets Philanthropy." He built the firm alongside senior pharmaceutical veterans Paul Lucas (former President and CEO of GlaxoSmithKline Canada) and Barry Markowsky (former VP Development and Director at GlaxoSmithKline Canada), pairing his own venture and operating experience with their large-pharma leadership backgrounds.

His track record includes several notable Canadian biotech ventures. He was associated with BIOX, which developed what is described as the world's first continuous-process biodiesel refinery (now operating with multiple facilities and a joint venture with World Energy of Houston); Defyrus, which developed the antiviral antibody therapy ZMapp used against Ebola — cited as the first antibody therapy proven effective in treating humans post-exposure to that disease; and Performance Plants in agricultural biotechnology. Today his primary operating focus is SignPost Cancer Dx Inc. (also branded SignPost Cancer Analytics / BreastDefense), a molecular-diagnostics venture in precision cancer detection where he serves as CEO, Founder, and Director. (Public sources do not detail his formal education.)

• Venture philanthropy / impact model: Induran invests to "accelerate ground breaking technologies that solve problems confronting humans," prioritizing life-saving products and social impact over pure financial return.
• Stage: Early-stage companies, consistent with seed-round angel activity.
• Sectors: Deep specialization in biotechnology — molecular diagnostics, antiviral and novel therapeutics, drug delivery, agricultural biotech, and biofuels/bioprocessing.
• Capital efficiency as a selection lens: Blaney frames ventures as engineering-driven products rather than sprawling companies. In his words: *"We are building a product, not a company. This results in maximum efficiency in the use of capital."*
• Co-investment approach: Induran partners with family offices, qualified investors, angel networks, and multinational corporations to syndicate funding for its portfolio companies.
• Market-driven adoption thinking: For SignPost/BreastDefense he emphasizes real, underserved demand — e.g., women who avoid mammography due to pain, radiation concerns, or misdiagnosis fears — as the driver of product uptake.